IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received an award of 171 deferred shares on May 7, 2026. The grant is recorded at a reference price of $178.64 per share and increases his directly held deferred share balance to 6,636 deferred shares.
Each deferred share is convertible into one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan. The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date on this award.
IQVIA Holdings Inc. director Colleen A. Goggins received a grant of 214 Deferred Shares on May 7, 2026, as part of her director compensation. Each deferred share is linked to one share of common stock and was valued at $178.64 per deferred share for reporting purposes.
After this grant, Goggins directly holds 5,114 Deferred Shares. These awards convert into common stock upon settlement and become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received an award of 228 deferred shares tied to the company’s common stock. The grant was priced at $178.64 per share and increased his directly held deferred share balance to 6,073.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, these deferred shares become settleable when Fasano ceases to be a director, upon a change in control of the company, or upon his death, and they have no expiry date.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl reported a grant of 185 deferred shares on May 7, 2026. These derivative securities were awarded at a reference price of $178.64 per deferred share and increase his directly held deferred share balance to 3,129.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. According to the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when Danhakl ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date.
IQVIA Holdings Inc. announced that its board of directors approved an additional $2 billion share repurchase authorization under its existing equity repurchase program, bringing the total remaining authorization to $3.2 billion. The program has no expiration date and does not require IQVIA to repurchase any specific amount of stock.
Repurchases may be made in open market transactions, block trades, or privately negotiated deals, and can be modified, extended, suspended or discontinued at any time based on IQVIA’s share price, corporate needs and overall market conditions.
IQVIA Holdings Inc. reports first-quarter 2026 results with revenues of $4,151 million, up 8.4% from 2025. Net income attributable to IQVIA rose to $274 million, and diluted earnings per share increased to $1.61 from $1.40.
Commercial Solutions revenue grew to $1,754 million, while Research & Development Solutions reached $2,397 million. Operating cash flow was strong at $618 million, supporting capital spending, acquisitions and $552 million of share repurchases. Total debt stood at $15,908 million with access to additional revolving credit capacity.
IQVIA Holdings Inc. reported strong first-quarter 2026 results, with revenue of $4,151 million, up 8.4% year-over-year, driven by both Commercial and R&D Solutions. Commercial Solutions revenue grew 11.6% to $1,754 million, while Research & Development Solutions reached $2,397 million, up 6.2%.
GAAP net income was $274 million with diluted EPS of $1.61. Adjusted EBITDA rose to $932 million, and Adjusted Diluted EPS increased to $2.90, up 7.4% year-over-year. Free Cash Flow was $491 million, up 15% and equal to 100% of Adjusted Net Income.
R&D Solutions contracted backlog was $34.2 billion, with about $8.9 billion expected to convert to revenue in the next twelve months and a book-to-bill of 1.04x. The company repurchased $552 million of stock and reaffirmed 2026 revenue and Adjusted EBITDA guidance while raising Adjusted Diluted EPS guidance to $12.65–$12.95.
IQVIA Holdings Inc Schedule 13G filing shows Vanguard Capital Management reports beneficial ownership of 12,714,783 shares of Common Stock as of 03/31/2026. The stake represents 7.49% of the class and Vanguard reports sole dispositive power over those shares.
The filing lists 1,687,800 shares as sole voting power and affirms holdings are reported on behalf of Vanguard affiliates and managed funds. The form is signed 04/30/2026 by Ashley Grim.
Stamps Sheila A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Sheila A. Stamps received a grant of 1,571 deferred shares linked to common stock as compensation. The award is priced at $160.68 per deferred share and increases her directly held deferred share balance to 4,210.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received a compensation grant of 1,571 deferred shares on common stock. These deferred shares are convertible into an equal number of IQVIA common shares upon settlement under the company’s Non-Employee Director Deferral Plan.
The award increased the director’s directly held deferred share balance to 6,465. The deferred shares become settleable when the director ceases to serve on the board, upon a change in control of the company, or upon the director’s death, and they do not have an expiry date.